Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)
Brief Summary: Asthma is a common, serious illness among children in the United States. While a low dose of inhaled corticosteroids (ICS) may effectively control symptoms, some children may require additional medications to maintain adequate asthma control. This study compares the effectiveness of a higher dose of ICS, ICS combined with a long-acting beta-agonist (LABA) medication, and ICS combined with a leukotriene receptor antagonist (LTRA) medication at reducing the impact and severity of asthma exacerbations that occur in children with mild to moderate persistent asthma.


Options:
A: Arm Label: Sequence #1; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #2; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #3; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #4; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #5; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #6; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Intervention Type: DRUG; Name: fluticasone propionate + montelukast; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6 | Intervention Type: DRUG; Name: fluticasone propionate; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6 | Intervention Type: DRUG; Name: fluticasone propionate + salmeterol; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6
B: Arm Label: Symbicort; Type: EXPERIMENTAL; Interventions: Drug: Budesonide/formoterol (SYMBICORT) pMDI | Arm Label: Budesonide; Type: EXPERIMENTAL; Interventions: Drug: Budesonide HFA pMDI | Intervention Type: DRUG; Name: Budesonide/formoterol (SYMBICORT) pMDI; Assigned to Arm(s): Symbicort | Intervention Type: DRUG; Name: Budesonide HFA pMDI; Assigned to Arm(s): Budesonide
C: Arm Label: Symbicort "as needed"+placebo Pulmicort bid; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol 'as needed' + budesonide placebo bid | Arm Label: Pulmicort bid + terbutaline "as needed"; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonode bid + terbutaline 'as needed' | Intervention Type: DRUG; Name: budesonide/formoterol 'as needed' + budesonide placebo bid; Assigned to Arm(s): Symbicort "as needed"+placebo Pulmicort bid | Intervention Type: DRUG; Name: budesonode bid + terbutaline 'as needed'; Assigned to Arm(s): Pulmicort bid + terbutaline "as needed"
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: budesonide and placebo | Intervention Type: DRUG; Name: budesonide/formoterol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: budesonide and placebo; Assigned to Arm(s): 2

Answer: A